Perfosfamide
Perfosfamide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cyhot cream with lidocaine | OTC monograph not final | 2018-02-20 |
| dch nerve pain relief roll-on | OTC monograph not final | 2023-06-28 |
| dch pain relief | OTC monograph not final | 2023-07-19 |
| dch pain relief roll-on | OTC monograph not final | 2023-06-08 |
| dermfree hemorrhoid | C200263 | 2024-08-15 |
| equate pain relief cream | C200263 | 2023-12-19 |
| fluconazole 4% / ibuprofen 2% / itraconazole 1% / terbinafine hcl 4% | unapproved drug other | 2019-04-24 |
| healmusz hemorrhoid fissure | C200263 | 2024-01-17 |
| lidocaine hcl 4 percent | C200263 | 2024-04-30 |
| lidocaine hcl 4% | OTC monograph not final | 2022-04-12 |
Show 16 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
84 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight loss | D015431 | HP_0001824 | — | — | — | — | 1 | 1 | 2 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 1 | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 3 | 4 | 4 | — | — | 10 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 2 | 4 | 3 | — | — | 8 |
| Lymphoid leukemia | D007945 | — | C91 | 1 | 4 | 3 | — | — | 7 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | 2 | — | — | 4 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | 1 | — | — | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | 1 | — | — | 2 |
| Preleukemia | D011289 | — | — | 1 | — | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | 1 | — | 1 | — | — | 2 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | — | — | 2 | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | 1 | 4 |
| Lymphoma | D008223 | — | C85.9 | 1 | 3 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | — | 1 | — | — | — | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | 1 | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 1 | — | — | — | 1 |
| Brain injuries | D001930 | — | S06.9 | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | 3 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | 2 | 3 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 4 | 4 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 4 | 4 |
| Sclerosis | D012598 | — | — | — | — | — | — | 4 | 4 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 4 | 4 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 3 | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 3 | 3 |
| Alcohol drinking | D000428 | EFO_0004329 | — | — | — | — | — | 3 | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 3 | 3 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 2 | 2 |
| Chronic disease | D002908 | — | — | — | — | — | — | 2 | 2 |
Show 93 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Perfosfamide |
| INN | perfosfamide |
| Description | 4-hydroperoxycyclophosphamide is a phosphorodiamide that is the active metabolite of the nitrogen mustard cyclophosphamide. It has potent antineoplastic and immunosuppressive properties. It has a role as an antineoplastic agent, an immunosuppressive agent, an alkylating agent, a metabolite and a drug allergen. It is a phosphorodiamide, a nitrogen mustard, a peroxol and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; isophosphoramide mustard derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=P1(N(CCCl)CCCl)NC(OO)CCO1 |
Identifiers
| PDB | — |
| CAS-ID | 39800-16-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL61511 |
| ChEBI ID | 196991 |
| PubChem CID | 38347 |
| DrugBank | — |
| UNII ID | U880A4FUDA (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 254 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use